Patent 7829685 was granted and assigned to Axikin Pharmaceuticals on November, 2010 by the United States Patent and Trademark Office.
Reagents which regulate human RC Kinase activity and reagents which bind to human RC Kinase gene products can be used to regulate this protein for therapeutic effects. Such regulation is particularly useful for treating chronic obstructive pulmonary disease, asthma, cancer, and diseases in which cell signaling is defective.